Gefitinib | 184475-35-2

Description :

Overview of Gefitinib

Gefitinib is a synthetic, pharmaceutical-grade substance that is classified as a tyrosine inhibitor of kinase. It is also available with the designation of active pharmaceutical component (API). It was specifically developed to be used in targeted cancer formulations and is widely employed in the production of anticancer drug formulations.

In pharmaceutical manufacturing, Gefitinib is valued for its selective molecular targeting, well-defined chemical profile, and compatibility with oral solid dosage forms. It is produced under highly regulated conditions to meet pharmacopeial and regulatory standards for purity, potency, and identity.

As a pharma chemical, Gefitinib is handled exclusively within licensed pharmaceutical manufacturing, formulation, and research environments.

Applications of Gefitinib

Pharmaceutical API Use

Gefitinib is used as an active pharmaceutical ingredient in the manufacture of targeted anticancer formulations, particularly for products designed to inhibit epidermal growth factor receptor (EGFR) activity. It is primarily formulated into oral solid dosage forms under strict regulatory oversight.

In oncology API portfolios, Gefitinib is commonly positioned alongside Erlotinib, Osimertinib, and Afatinib for targeted therapy product development.

Finished Dosage Form Manufacturing

Gefitinib is used in the production of oral tablets where precise dose uniformity, controlled bioavailability, and chemical stability are required. Its physicochemical properties support consistent formulation performance in solid dosage manufacturing.

Manufacturing is carried out under GMP-compliant conditions due to the compound’s high potency and therapeutic specificity.

Pharmaceutical Research & Reference Use

Gefitinib is also utilised as a reference chemical in research on pharmaceuticals, as well as quality control and the development of analytical methods. It is used in dissolution profiling, stability studies and comparative assessment of EGFR inhibitors.

In oncology research settings, it may be referenced alongside Lapatinib and Crizotinib for kinase inhibition comparison studies.

Safety & Handling Guidelines

• Keep the items in a cool, humid, dry and well-controlled area
• Be sure to protect yourself from moisture and light
• Seal containers well and keep them clearly labelled
• Avoid contact with the air or direct contact with API powder
• Use appropriate personal protective equipment
• Handle only in regulated pharmaceutical manufacturing areas
• Dispose of waste according to oncology API regulatory guidelines
  
  
  

Where to Buy Gefitinib?

Gefitinib Manufacturer

Gefitinib is manufactured for pharmaceutical use under stringent GMP conditions to ensure consistent quality, high purity, and regulatory compliance for oncology drug production.

Gefitinib Supplier & Distributor

Pharma-grade Gefitinib API is supplied in conforming packaging that is suitable for licensed pharmaceutical producers or oncology-related formulation facilities. As a supplier of pharmaceutical chemicals and distributor, Chemicalbull Pvt. Ltd. ensures secure sourcing through COA, MSDS, and documents for regulatory compliance.

MSDS for Gefitinib

The MSDS for Gefitinib includes detailed information on chemical dangers, safe handling procedures, the requirements for storage, exposure control and emergency response methods. It should be reviewed prior to making or preparing for laboratory handling.

Frequently Asked Questions (FAQs)

1. What is Gefitinib?
   

   Gefitinib is a synthetic pharmaceutical compound supplied as an active pharmaceutical ingredient and used in the manufacture of targeted anticancer drug formulations.
   
   

2. What is the mechanism of action of Gefitinib?
   

   Gefitinib works by selectively inhibiting the tyrosine kinase activity of the epidermal growth factor receptor (EGFR), thereby interfering with cancer cell growth and proliferation pathways.
   
   

3. What is the structure of Gefitinib?
   

   Gefitinib has a quinazoline-based molecular structure, which is responsible for its selective binding to the EGFR tyrosine kinase domain.